Proteome Sciences PLC Notice of Results (7216K)
11 July 2017 - 9:00PM
UK Regulatory
TIDMPRM
RNS Number : 7216K
Proteome Sciences PLC
11 July 2017
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Notice of Results
Proteome Sciences will announce its interim results for the six
months ended 30 June 2017 on 25 July 2017.
For further information:
Proteome Sciences plc
Dr Jeremy Haigh, Chief Executive Officer Tel:
+44 (0)20 7043 2116
Dr Ian Pike, Chief Scientific
Officer
Geoff Ellis, Finance Director
finnCap Limited (Nominated
Adviser/Broker) Tel: +44 (0)20 7220
Geoff Nash/James Thompson 0500
Tony Quirke (broking)
IFC Advisory (Financial PR and IR)
Tim Metcalfe/Graham Tel: +44 (0)20 3053
Herring/Miles Nolan 8671
Notes for editors:
Proteome Sciences is a leader in applied proteomics offering
high sensitivity, proprietary technologies and workflows for
mapping cell signalling pathways (SysQuant(R) , TMTcalibrator(TM) )
and for the discovery, validation and assay development of protein
biomarkers. The company has its headquarters in London, UK, with
laboratory facilities in Frankfurt, Germany from where the PS
Biomarker Services(TM) division provides outsourced proteomics
services and proprietary biomarker assays to biopharmaceutical and
diagnostics companies and to academia.
Proteome Sciences has patented several novel protein biomarkers
for diagnostic and treatment applications in important areas of
human therapeutics such as cancer, stroke and Alzheimer's disease,
and these are available for license.
This announcement contains inside information for the purpose of
Article 7 of EU Regulation 596/2014.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORLLFSIDVILLID
(END) Dow Jones Newswires
July 11, 2017 07:00 ET (11:00 GMT)
Proteome Sciences (LSE:PRM)
Historical Stock Chart
From Apr 2024 to May 2024
Proteome Sciences (LSE:PRM)
Historical Stock Chart
From May 2023 to May 2024